Boston Scientific's (BSX) 2026 guidance is "reasonable", but stock sentiment is being driven by the Q1 performance of its Pulsed Field Ablation and Left Atrial Appendage Closure System products, RBC Capital Markets analysts said in a Thursday note.

Analysts said that the company's 2026 guidance factors in growth contributions of about 250 basis points from Electrophysiology, 200 basis points from Watchman, and the remaining 550 basis points from the base business.

RBC said that "cadence through the year, including for Q1, can be choppy and remains in high focus among investors with most cautious ahead of the print."

Analysts said that the company has multiple growth drivers across its businesses, including its renal denervation business, intravascular lithotripsy, and the Penumbra acquisition, among others.

RBC said that Boston Scientific's stock is trading at its 5-year lows, failing to fully reflect its growth profile and financial strength.

Analysts have an outperform rating on the stock and a $115 price target.

Price: 62.86, Change: +0.86, Percent Change: +1.39